MBRX News

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Moleculin to Participate in the Virtual Investor Closing Bell Series

Moleculin Announces Reverse Stock Split

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented